Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome

  title={Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome},
  author={Lucrezia Laterza and Gianluca Ianiro and Iolanda Scoleri and Rosario Landi and Giovanni Bruno and Franco Scaldaferri and Eleonora Gaetani and Mariachiara Campanale and Antonio Gasbarrini},
  journal={Expert Opinion on Pharmacotherapy},
  pages={607 - 615}
Introduction: Rifaximin is a non-absorbable, semisynthetic antibiotic that acts as an inhibitor of bacterial RNA synthesis, with a broad spectrum of antibacterial activity. Due to its poor absorption, rifaximin has an increased exposure to the intestine, thus it is suitable for the treatment of many gastrointestinal (GI) diseases. In irritable bowel syndrome (IBS) pathogenesis, gut microbiota impairment may play a major role. The possibility of modulating intestinal bacteria using antibiotics… 
Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
Clinical studies have demonstrated that rifaximin improves symptoms associated with IBS, such as bloating, flatulence, stool consistency, and abdominal pain, and has a side-effect profile similar to placebo, which presents as a safe and beneficial addition to the current management options for IBS.
Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study.
  • E. Safwat, M. Salah, H. Hussein
  • Medicine
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  • 2020
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.
Rifaximin has been demonstrated to exert beneficial effects on cognitive function in patients with HE, and also to prevent the development of SBP, to reduce endotoxemia and to improve hemodynamics in cirrhotics, linked to a shift in gut microbes functionality, triggering the production of favorable metabolites.
Rifaximin Therapy in Patients of Irritable Bowel Syndrome Without Constipation Randomized Controlled Trial
Prescribing rifaximin should be considered in treatment of IBS patients as it provides a promising treatment option which is cost effective and has fewer side effects.
Pharmacological and Clinical Treatment of Irritable Bowel Syndrome
An overview on drugs that are currently available for IBS therapy with regard to the type of the disease is provided and selected complementary and alternative (CAM) medicine methods that have been proven effective in clinical tests are introduced.
Irritable Bowel Syndrome: The Most Common Presentation, Severity Ranking and Therapeutic Regimens among Patients Attending Outpatient
Antispasmodics usage in this study show high effectiveness for IBS patients especially those with crampy abdominal pain and diarrhea, and could be unnecessary medication that could aggravate bowel symptoms and have adverse effects on the long term.
Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?
In conclusion, ME represents a novel entity that is attracting increasing interest and the growing epidemiologic trend confirms that it will become a common condition in clinical practice.
Pharmacokinetics and pharmacology to drugs used for control of emerging cryptosporidiosis and toxoplasmosis in livestock and humans
The main aim of this article is to discuss the current significance of available chemotherapeutic agents in relation to their effectiveness in order to cure or decrease the potential of economic losses caused these protozoan infections.
The Mexican consensus on irritable bowel syndrome.


Rifaximin for the treatment of irritable bowel syndrome
The evidence supports rifaximin as an emerging treatment for IBS, and strategies for appropriate patient selection need to be further developed, and continued efficacy of rifaxIMin over repeated treatment courses needs to be better characterized.
The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome
Whether the nonabsorbed antibiotic rifaximin is more effective than placebo in reducing symptoms in adults with IBS is determined.
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections
Rifaximin is effective in the treatment and prevention of travelers’ diarrhea due to Escherichia coli-predominant bacterial pathogens and may be useful in other enteric infectious diseases, including Clostridium difficile colitis, pediatric bacterial diarrhea and Helicobacter pylori gastritis.
Rifaximin Therapy of Irritable Bowel Syndrome
The pharmacokinetics, in vitro susceptibility profile, and efficacy and safety data from clinical trials of rifaximin treatment of IBS are discussed.
Rifaximin systemic absorption in patients with ulcerative colitis
Ulcerative colitis is a chronic in ̄ammatory disease of the large intestine, characterised by alternate phases of activity and remission. Its aetiology is unknown, but circumstantial evidence
Rifaximin therapy for patients with irritable bowel syndrome without constipation.
Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools.
Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential
This antibiotic has, therefore, little value outside the enteric area and this will minimize both antimicrobial resistance and systemic adverse events.
Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.
Overall, rifaximin may be useful as an alternative therapy in hepatic encephalopathy but more data are needed to better define its clinical potential in infectious diarrhoea, diverticular disease and as antibacterial prophylaxis prior to colorectal surgery.
Rifaximin pharmacology and clinical implications
Rifaximin contributes to restore gut microflora imbalance, becoming an important therapeutic agent in several organic and functional gastrointestinal diseases such as hepatic encephalopathy, small intestine bacterial overgrowth, inflammatory bowel disease and colonic diverticular disease.
Bile Acids Improve the Antimicrobial Effect of Rifaximin
It is suggested that rifaximin may be more effective in the treatment of infections in the small intestine, due to the higher concentration of bile in this region of the gastrointestinal tract than in the colon.